Sanofi: new approval for Dupixent in Canada

(CercleFinance.com) - Sanofi announced on Thursday that its flagship drug Dupixent has been approved in Canada for the treatment of children aged one year or older with eosinophilic esophagitis.


This approval expands the initial approval granted in May 2023 by Health Canada for the same indication, but for patients aged 12 years or older and weighing at least 40 kg.

Eosinophilic esophagitis - a chronic progressive disease of the esophagus - is caused by inflammation that damages the organ and impairs its function, leading to heartburn, vomiting, refusal to eat and stunted growth.

Dupixent, a fully human monoclonal antibody, was first approved in Canada in 2017 for the treatment of adults with moderate to severe atopic dermatitis.

This is its ninth indication in Canada and its second in gastroenterology.


Copyright (c) 2024 CercleFinance.com. All rights reserved.